effect of pomegranate peel extract on non-alcoholic fatty liver disease

The effect of supplementation with pomegranate peel extract on liver enzymes, hs-CRP and lipid profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind clinial trial.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20091114002709N58

Enrollment

Registered

2022-01-11

Start date

2021-11-06

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: consumption of two capsules per day (each of them containing 500mg extract of pomegranate peel ) for 12 weeks. Intervention 2: Control group: consumption of two pl

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Alanine aminotransferase (ALT) greater than 20 IU/L for women and greater than 30 IU/L for men. Evidence of fatty liver in ultrasonography with a score of 1 or 2. Being volunteer or Wishing to attend. age: 30 to 60 years. BMI: 25Kg/m2 to 35Kg/m2.

Exclusion criteria

Exclusion criteria: Other acute or chronic hepatic disorders cardiovascular disease, renal disease, infectious disease, diabetes, cancer. hemorrhoid or chronic constipation. intensive weight loss or weight gain during 3 months prior to intervention. Any use of antioxidant supplements during 1 month prior to intervention. Use of hepatotoxic medications during last month. Use of lipid lowering medications or insulin-sensitizing medications. Problem in blood coagulation. Dysmenorrhea or excessive bleeding during menses. History of benign tumours. Consumption of alcohol, addictive drugs and smoking. The patient's unwillingness to continue cooperation. pregnancy. lactation.

Design outcomes

Primary

Measure	Time frame
Alanine aminotransferase (ALT). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Aspartate aminotransferase (AST). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.	—

Secondary

Measure	Time frame
High density lipoprotein cholesterol (HDL-C). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Low density lipoprotein cholesterol (LDL-C). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Alkaline phosphatase (ALP). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Total cholesterol (TC). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Triglyceride (TG). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;High sensitive reactive protein (hs-CRP). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.	—

Measure

Time frame

High density lipoprotein cholesterol (HDL-C). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Low density lipoprotein cholesterol (LDL-C). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Alkaline phosphatase (ALP). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Total cholesterol (TC). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Triglyceride (TG). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;High sensitive reactive protein (hs-CRP). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzad Shidfar

Iran University of Medical Sciences

Shidfar.f@iums.ac.ir+98 21 8862 2755

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026